Skip to main content

Crescent Biopharma, Inc 8-K, filed Oct 15, 2026

Crescent Biopharma, Inc. (CBIO)

8-K 2026-10-15 For: 2026-10-15
View Original
Added on October 23, 2026

About this 8-K

Crescent Biopharma, Inc filed this 8-K on October 15, 2026.

Crescent Biopharma began ASCEND chemotherapy-combination enrollment, plans additional ADC combination studies, received IND allowance for CR-002, and expects APOLLO initiation in the fourth quarter of 2026 and initial data in the second half of 2027. AI summary

Items reported

  • Item 8.01: Other events